/

Società

As

Non verificato

AstraZeneca

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaMedicina - VarieSalute

114 comunicati stampa

Guarda tutti i comunicati

24/06/2026

Mercato del lavoro

Industria

Biotecnologia

Sanità

Salute

Farmaceutica

Oncologia

AstraZeneca and YMCA of the USA Announce Landmark Partnership Aimed to Address Gaps in Cancer Care

Fonte

Emittente

1.00

0

12/06/2026

Igiene alimentare

Terza età

Medicina - Varie

Biotecnologia

Salute

Vetrine/Shopping

Farmaceutica

Oncologia

TRUQAP® (capivasertib) combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer

Fonte

Emittente

1.00

0

02/06/2026

Oncologia

Salute

Medicina - Varie

Scienza

Farmaceutica

Biotecnologia

Industria

Camizestrant Combination Delayed Time to First Progression by 55% and to Second Progression by 37% in Patients With Advanced HR-positive Breast Cancer With an Emergent ESR1 Tumor Mutation in SERENA-6 Trial

Fonte

Emittente

1.00

0

01/06/2026

Scienza

Medicina - Varie

Biotecnologia

Salute

Farmaceutica

Sanità

Oncologia

Eventi

Industria

IMFINZI® (durvalumab) plus IMJUDO® (tremelimumab-actl) combined with lenvatinib and TACE reduced the risk of disease progression or death by 30% in embolization-eligible unresectable liver cancer in EMERALD-3 Phase III trial

Fonte

Emittente

1.00

0

29/05/2026

Oncologia

Salute

Medicina - Varie

Scienza

Farmaceutica

Biotecnologia

Industria

IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer

Fonte

Emittente

1.00

0

22/05/2026

Industria

Scienza

Medicina - Varie

Igiene alimentare

Biotecnologia

Salute

Farmaceutica

Oncologia

DATROWAY® (datopotamab deruxtecan-dlnk) approved in the US as first TROP2-directed antibody drug conjugate for 1st-line treatment of patients with metastatic triple-negative breast cancer who are not PD-1/PD-L1 inhibitor candidates

Fonte

Emittente

1.00

0

22/05/2026

Scienza

Medicina - Varie

Biotecnologia

Salute

Farmaceutica

Sanità

Oncologia

Eventi

Industria

AstraZeneca to showcase Phase III data in liver, breast and bladder cancers and potential first-in-class rare disease therapy at ASCO 2026

Fonte

Emittente

1.00

0

18/05/2026

BAXFENDY approved in the US as the first and only aldosterone synthase inhibitor treatment for adults with hypertension

Fonte

Emittente

1.00

0

16/05/2026

Industria

Scienza

Medicina - Varie

Igiene alimentare

Biotecnologia

Salute

Farmaceutica

Oncologia

ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US for two new indications for patients with HER2-positive early breast cancer

Fonte

Emittente

1.00

0

14/05/2026

Industria

Oncologia

Salute

Medicina - Varie

Scienza

Farmaceutica

Biotecnologia

Perioperative IMFINZI® (durvalumab) plus neoadjuvant EV showed statistically significant and clinically meaningful improvements in event-free survival and overall survival in muscle-invasive bladder cancer in the Phase III VOLGA trial

Fonte

Emittente

1.00

0

Seguaci

0

Compatibilità

0